Sign in
4

Changes in Ownership

Stoke Therapeutics, Inc. Filed Acc 0001415889-25-023589

GENERAL COUNSEL & CORP SEC sold 22,117 shares at an average $20.11 ($444,809)

  • GENERAL COUNSEL & CORP SEC acquired 10,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-08-29 Option exercise 10b5-1 +850 $7.07 $6,010 24,798 D: show line 1 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-08-29 Sale 10b5-1 −850 $20.00 $17,000 23,948 D: show line 2 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-09-02 Option exercise 10b5-1 +9,150 $7.07 $64,691 33,098 D: show line 3 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-09-02 Sale 10b5-1 −14,922 $20.14 $300,492 18,176 D: show line 4 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-09-03 Sale 10b5-1 −6,345 $20.07 $127,317 11,831 D: show line 5 in the form
Open-market sales · 22,117 sh · avg $20.11 · $444,809

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-08-29 Option exercise · Stock Option (Right to Buy) 10b5-1 −850 24,951 D: show line 6 in the form
Allan Jonathan GENERAL COUNSEL & CORP SEC 2025-09-02 Option exercise · Stock Option (Right to Buy) 10b5-1 −9,150 15,801 D: show line 7 in the form
Loading xslF345X05/form4-09032025_090917.xml…